ClinicalTrials.gg
CompletedNCT04023227PARACHUTE-HFUpdated May 11, 2026Results posted

Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC

A Phase 4 interventional study of Sacubitril/valsartan and Enalapril in Chagas Disease and Heart Failure, sponsored by Novartis Pharmaceuticals. Completed at 79 sites in 4 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
922
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 28 studies in Chagas Disease with a site in Brazil — 2 open to participants now, 3 under way, 1 of them phase 3. Chagas Disease · Brazil.

Enrollment
3rd of 21
922 · median 60
Started
2019
the only one that year
Phase 4
4 of 28
none open now
Registered
23rd of 28
by date
Lead sponsor
2 of 28
Novartis Pharmaceuticals

Among the 28 studies in Chagas Disease with a site in Brazil, this one is the 3rd largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2019, is one of 4 in phase 4, and was the 23rd registered.

Chagas Disease

73 studies on the registry are indexed under Chagas Disease; 5 are open to participants now.

Browse Chagas Disease studies →

Open to participants now

2 of the 28 studies in Chagas Disease with a site in Brazil are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 3 Chagas Disease studies recruiting now, 1 sets no upper age limit and 2 stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Chagas Disease with a site in Brazil, or all of them as a file.
02

Study summary

The purpose of this study was to evaluate the effect of sacubitril/valsartan 200 mg BID compared with enalapril 10 mg BID, in addition to conventional heart failure (HF) treatment, in improving a hierarchical composite of cardiovascular (CV) events (i.e. CV death or the occurrence of first HF hospitalization) and causing a greater reduction in n terminal prohormone of brain natriuretic peptide (NT-proBNP, at Week 12 from Baseline) in participants with HF with reduced ejection fraction (HFrEF) caused by chronic Chagas' cardiomyopathy (CCC).

Read the detailed description

This was a multinational, multicenter, parallel-group, prospective, randomized, open-label, with blinded-endpoint adjudication, active-controlled study. The target projected sample size was approximately 900 participants (450 in each arm). It was estimated that approximately 1800 participants would be screened at sites in Latin America, including Argentina, Brazil, Colombia, and Mexico.

Participants who met the eligibility requirements were randomly assigned in a 1:1 ratio to receive sacubitril/valsartan (target dose of 200 mg twice daily) or enalapril (target dose of 10 mg twice daily), in addition to their usual therapy, stratified by country, using a central, concealed, web-based, automated randomization system. Both groups entered a titration period of 3 to 6 weeks, aiming to achieve the target dose of sacubitril/valsartan 200 mg twice daily or enalapril 10 mg twice daily. The study follow-up succeeded the titration period and was to last until a total number of 302 events was reached and all randomized participants had a minimum follow-up of 12 weeks.

03

Conditions studied

  • Chagas Disease
  • Heart Failure

Keywords

  • Chagas' disease
  • heart failure
  • angiotensin receptor-neprilysin inhibitor
  • ARNI
  • ARB
  • ACEI
  • sacubitril/valsartan
  • enalapril
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or female ≥ 18 years of age
  • Diagnosis of Class II-IV HFrEF established by:

    1. ≤ 40% within 12 months prior to Visit 1 made by any local measurement using echocardiography, multiple gated acquisition scan (MUGA), computerized tomography (CT) scanning, magnetic resonance imaging (MRI), or ventricular angiography, provided no subsequent measurement above 40% AND
    2. NT-proBNP ≥ 600 pg/mL (or BNP ≥ 150 pg/mL) at Visit 1 OR
    3. NT-proBNP ≥ 400 pg/mL (or BNP ≥ 100 pg/mL) at Visit 1 and a hospitalization for HF within the last 12 months
  • Chagas' disease diagnosis confirmed by at least two different serological tests for anti-Trypanosoma cruzi based on different principles or with different antigenic preparations, such as: enzyme-linked immunosorbent assay [ELISA], indirect immunofluorescence [IFI], indirect hemagglutination [IHA], western blot (WB), chemiluminescent immunoassay (CLIA). If documented history is not available, the tests may be performed during the screening

Key Exclusion Criteria:

  • Patients with history of suspected or proven angioedema or unable to tolerate ACEIs, ARBs or ARNI (e.g., due to cough, hypotension, renal dysfunction, hyperkalemia)
  • Use of sacubitril/valsartan in the past 3 months
  • Patients requiring continuous intravenous inotropic therapy or with indication of advanced support intervention for HF:

    1. already on list for a heart transplantation
    2. with current indication of left ventricular assist device, or cardiac resynchronization therapy (CRT)
  • Systemic systolic blood pressure lower than 95 mmHg or symptomatic hypotension
  • Serum potassium > 5.2 mmol/L
  • Estimated (eGFR) \< 30 mL/min/1.73 m2 of body surface area
  • Severe gastrointestinal form of chronic Chagas' disease (demonstrated megaesophagus and/or important megacolon, e.g.: with compromised oral intake or surgical indication).
  • Clinical conditions or systemic diseases limiting proper patient participation
  • Pregnant or nursing women or women of unless they are using highly effective methods of
  • Presence of other cardiac conditions:

    1. Previous cardiac surgery
    2. Heart failure where, in the Investigator's judgement, there is a possible alternative primary etiology e.g., due to coronary artery disease, valve disease, congenital heart disease or other causes.
    3. Untreated arrhythmia or serious conduction disease e.g., bradyarrhythmias, atrial fibrillation with rapid ventricular response, second or third degree atrioventricular block, etc.
    4. Primary uncorrected valvar pathology like moderate to severe aortic stenosis, mitral stenosis and primary mitral regurgitation
    5. Planned organ transplantation (or in listing for transplantation), planned cardiac or other major surgery (including ventricular assist device implantation)
  • History of of any organ system within the past 5 years.
  • Current confirmed COVID19 infection
  • Past COVID19 infection with persistent symptom burden suspected due to COVID19 (persistent symptoms may include, but are not limited to, continued cough, breathing difficulty, muscle/joint aches, and gastrointestinal symptoms from the time of COVID19 infection onward)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
922 participants (actual)

Study arms

  • Experimental
    Sacubitril/valsartan

    Participants received 3 to 6 weeks of titrated dosing with sacubitril/valsartan to achieve the target dose of 200 mg twice daily.

    Drug: Sacubitril/valsartan

  • Active comparator
    Enalapril

    Participants received 3 to 6 weeks of titrated dosing with enalapril to achieve the target dose of 10 mg twice daily.

    Drug: Enalapril

Interventions

  • DrugSacubitril/valsartan

    Drug pages: Sacubitril · Valsartan

    Participants randomized to sacubitril/valsartan who were previously treated with angiotensin-converting enzyme inhibitors (ACEIs) had a 36-hour washout prior to receiving oral treatment with 50, 100, or 200 mg, film-coated tablets.

    Also known as: LCZ696; Entresto; Vymada

  • Oral treatment with 5 or 10 mg tablets.

    Also known as: Renitec

06

What researchers measure

Primary outcomes

  1. Hierarchical Composite Endpoint Composed of Time to Cardiovascular (CV) Death, Time to First Heart Failure (HF) Hospitalization, and Relative Change in NT-proBNP From Baseline to Week 12

    The primary efficacy endpoint was analyzed using the win ratio approach comparing every participant in the sacubitril/valsartan arm to every participant in the enalapril arm to determine a winner. A winner in the pair-wise comparison had a delayed time to the occurrence of CV death; if time to the occurrence of CV death was censored, a winner had a delayed time to the occurrence of first HF hospitalization event; if the times to both CV events were censored, a winner had a more favorable (less increase or more decrease) change in NT-proBNP between Baseline and Week 12. The estimated win ratio was defined as the total number of winners in the sacubitril/valsartan arm divided by the total number of winners in the enalapril arm. A win ratio \>1 represents a favorable outcome for the study drug being assessed.

    Time frame: Total follow-up time up to approximately 36 months

  2. Percentage of Participants Who Died From Cardiovascular Causes

    Time frame: Total follow up time up to approximately 36 months

  3. Percentage of Participants With First Hospitalization for Worsening Heart Failure

    Time frame: Total follow up time up to approximately 36 months

  4. Change From Baseline to Week 12 in NT-proBNP Levels

    Geometric mean factor change was derived from a linear regression model of log(NT-proBNP), adjusted for country and baseline value.

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Percentage of Participants With First Hospitalization Due to Heart Failure or Death From Cardiovascular Causes

    Time frame: From the date of randomization to the first occurrence (total follow up time up to approximately 36 months)

  2. Percentage of Participants Who Died From Any Cause

    Time frame: From date of randomization until the date of death from any cause assessed up to the end of the study, up to approximately 36 months

  3. Number of Participants Who Had Sudden Death or Resuscitated Sudden Cardiac Arrest

    Time frame: From date of randomization until the date of the sudden death or resuscitated sudden cardiac arrest assessed up to the end of the study, up to approximately 36 months

  4. Number of Participants Who Had Visits to an Emergency Room Due to Heart Failure (HF) Where Intravenous Therapy Was Required

    Time frame: From the date of randomization up to end of study. Total follow up time up to approximately 36 months.

  5. Number of Days Alive and Out of the Hospital

    The duration of hospital-free survival within 1 year from randomization was summarized.

    Time frame: From the date of randomization up to end of study. Total follow up time up to approximately 36 months.

  6. Number of Hospitalizations Due to Heart Failure (HF) or Death Due to Cardiovascular (CV) Causes (Recurrent Events)

    Time frame: From the date of randomization up to end of study. Total follow up time up to approximately 36 months.

Other outcomes

  1. Number of Ventricular Fibrillation or Sustained Ventricular Tachycardia

    The number of ventricular fibrillation or sustained ventricular tachycardia needing specific pharmacological, electrical or other treatment was determined.

    Time frame: From the date of randomization up to end of study. Total follow up time up to approximately 36 months.

  2. Number of Anti-tachycardia Pacing or Shock Therapies

    Time frame: From the date of randomization up to end of study. Total follow up time up to approximately 36 months.

07

Results

Posted May 11, 2026

Participant flow

Participant flow — Overall Study
MilestoneSacubitril/ValsartanEnalapril
Started462460
Completed333318
Not completed129142
Withdrew: Withdrawal of participant consent28
Withdrew: Death127134

Outcome measures

PrimaryHierarchical Composite Endpoint Composed of Time to Cardiovascular (CV) Death, Time to First Heart Failure (HF) Hospitalization, and Relative Change in NT-proBNP From Baseline to Week 12

The primary efficacy endpoint was analyzed using the win ratio approach comparing every participant in the sacubitril/valsartan arm to every participant in the enalapril arm to determine a winner. A winner in the pair-wise comparison had a delayed time to the occurrence of CV death; if time to the occurrence of CV death was censored, a winner had a delayed time to the occurrence of first HF hospitalization event; if the times to both CV events were censored, a winner had a more favorable (less increase or more decrease) change in NT-proBNP between Baseline and Week 12. The estimated win ratio was defined as the total number of winners in the sacubitril/valsartan arm divided by the total number of winners in the enalapril arm. A win ratio \>1 represents a favorable outcome for the study drug being assessed.

Time frame:
Total follow-up time up to approximately 36 months
Reported as:
Number · wins
Hierarchical Composite Endpoint Composed of Time to Cardiovascular (CV) Death, Time to First Heart Failure (HF) Hospitalization, and Relative Change in NT-proBNP From Baseline to Week 12
winsSacubitril/ValsartanEnalapril
Hierarchical Composite Endpoint Composed of Time to Cardiovascular (CV) Death, Time to First Heart Failure (HF) Hospitalization, and Relative Change in NT-proBNP From Baseline to Week 1210308667097
SecondaryPercentage of Participants With First Hospitalization Due to Heart Failure or Death From Cardiovascular Causes
Time frame:
From the date of randomization to the first occurrence (total follow up time up to approximately 36 months)
Reported as:
Number · percentage of participants
Percentage of Participants With First Hospitalization Due to Heart Failure or Death From Cardiovascular Causes
percentage of participantsSacubitril/ValsartanEnalapril
Percentage of Participants With First Hospitalization Due to Heart Failure or Death From Cardiovascular Causes33.536.7
SecondaryPercentage of Participants Who Died From Any Cause
Time frame:
From date of randomization until the date of death from any cause assessed up to the end of the study, up to approximately 36 months
Reported as:
Number · percentage of participants
Percentage of Participants Who Died From Any Cause
percentage of participantsSacubitril/ValsartanEnalapril
Percentage of Participants Who Died From Any Cause27.929.1
SecondaryNumber of Participants Who Had Sudden Death or Resuscitated Sudden Cardiac Arrest
Time frame:
From date of randomization until the date of the sudden death or resuscitated sudden cardiac arrest assessed up to the end of the study, up to approximately 36 months
Reported as:
Number · participants
Number of Participants Who Had Sudden Death or Resuscitated Sudden Cardiac Arrest
participantsSacubitril/ValsartanEnalapril
Number of Participants Who Had Sudden Death or Resuscitated Sudden Cardiac Arrest4639
SecondaryNumber of Participants Who Had Visits to an Emergency Room Due to Heart Failure (HF) Where Intravenous Therapy Was Required
Time frame:
From the date of randomization up to end of study. Total follow up time up to approximately 36 months.
Reported as:
Number · participants
Number of Participants Who Had Visits to an Emergency Room Due to Heart Failure (HF) Where Intravenous Therapy Was Required
participantsSacubitril/ValsartanEnalapril
Number of Participants Who Had Visits to an Emergency Room Due to Heart Failure (HF) Where Intravenous Therapy Was Required2321
SecondaryNumber of Days Alive and Out of the Hospital

The duration of hospital-free survival within 1 year from randomization was summarized.

Time frame:
From the date of randomization up to end of study. Total follow up time up to approximately 36 months.
Reported as:
Mean · days
Number of Days Alive and Out of the Hospital
daysSacubitril/ValsartanEnalapril
Number of Days Alive and Out of the Hospital339 ± 72338 ± 71
SecondaryNumber of Hospitalizations Due to Heart Failure (HF) or Death Due to Cardiovascular (CV) Causes (Recurrent Events)
Time frame:
From the date of randomization up to end of study. Total follow up time up to approximately 36 months.
Reported as:
Number · hospitalizations
Number of Hospitalizations Due to Heart Failure (HF) or Death Due to Cardiovascular (CV) Causes (Recurrent Events)
hospitalizationsSacubitril/ValsartanEnalapril
Number of Hospitalizations Due to Heart Failure (HF) or Death Due to Cardiovascular (CV) Causes (Recurrent Events)289316
Other pre-specifiedNumber of Ventricular Fibrillation or Sustained Ventricular Tachycardia

The number of ventricular fibrillation or sustained ventricular tachycardia needing specific pharmacological, electrical or other treatment was determined.

Time frame:
From the date of randomization up to end of study. Total follow up time up to approximately 36 months.
Reported as:
Number · events
Number of Ventricular Fibrillation or Sustained Ventricular Tachycardia
eventsSacubitril/ValsartanEnalapril
Number of Ventricular Fibrillation or Sustained Ventricular Tachycardia4232
Other pre-specifiedNumber of Anti-tachycardia Pacing or Shock Therapies
Time frame:
From the date of randomization up to end of study. Total follow up time up to approximately 36 months.
Reported as:
Number · events
Number of Anti-tachycardia Pacing or Shock Therapies
eventsSacubitril/ValsartanEnalapril
Number of Anti-tachycardia Pacing or Shock Therapies1713
Post-hocAll Collected Deaths

On-treatment deaths: from first dose of study treatment to 30 days following the last dose of study treatment at the end of treatment phase. Survival follow-up deaths: from Day 31 after last dose of study treatment up to study completion.

Time frame:
On-treatment deaths: Up to approximately 55 months. Post-treatment survival follow-up deaths: Up to an additional 8 months.
Reported as:
Count of participants · Participants
All Collected Deaths
ParticipantsSacubitril/ValsartanEnalapril
On-treatment deaths127134
Post-treatment survival follow-up deaths20
All deaths129134
PrimaryPercentage of Participants Who Died From Cardiovascular Causes
Time frame:
Total follow up time up to approximately 36 months
Reported as:
Number · percentage of participants
Percentage of Participants Who Died From Cardiovascular Causes
percentage of participantsSacubitril/ValsartanEnalapril
Percentage of Participants Who Died From Cardiovascular Causes23.825.4
PrimaryPercentage of Participants With First Hospitalization for Worsening Heart Failure
Time frame:
Total follow up time up to approximately 36 months
Reported as:
Number · percentage of participants
Percentage of Participants With First Hospitalization for Worsening Heart Failure
percentage of participantsSacubitril/ValsartanEnalapril
Percentage of Participants With First Hospitalization for Worsening Heart Failure22.124.1
PrimaryChange From Baseline to Week 12 in NT-proBNP Levels

Geometric mean factor change was derived from a linear regression model of log(NT-proBNP), adjusted for country and baseline value.

Time frame:
Baseline to Week 12
Reported as:
Geometric mean · picograms per milliliter
Change From Baseline to Week 12 in NT-proBNP Levels
picograms per milliliterSacubitril/ValsartanEnalapril
Change From Baseline to Week 12 in NT-proBNP Levels0.62 (0.56 to 0.69)0.91 (0.82 to 1.01)

Adverse events

Collected over Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 55 months. Deaths were also collected in the survival follow-up phase from 31 days after last dose of study medication until the end of the study, for an additional 8 months. These were not considered AEs.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sacubitril/@Valsartan129/462 (27.9%)169/462 (36.6%)102/462 (22.1%)
Enalapril134/460 (29.1%)183/460 (39.8%)145/460 (31.5%)
All Participants (Sacubitril/Valsartan and Enalapril)263/922 (28.5%)352/922 (38.2%)247/922 (26.8%)
Most frequent serious events
Showing 10 of 244
Most frequent serious events
EventSacubitril/@ValsartanEnalaprilAll Participants (Sacubitril/Valsartan and Enalapril)
Cardiac failureCardiac disorders14/46223/46037/922
Acute kidney injuryRenal and urinary disorders15/46216/46031/922
HypotensionVascular disorders11/46215/46026/922
Ischaemic strokeNervous system disorders14/46214/46028/922
Ventricular tachycardiaCardiac disorders14/46211/46025/922
Ventricular arrhythmiaCardiac disorders12/46213/46025/922
Pneumonia bacterialInfections and infestations8/46212/46020/922
Septic shockInfections and infestations12/4627/46019/922
Cardiac failure acuteCardiac disorders8/46211/46019/922
PneumoniaInfections and infestations8/46210/46018/922
Most frequent other events
Most frequent other events
EventSacubitril/@ValsartanEnalaprilAll Participants (Sacubitril/Valsartan and Enalapril)
CoughRespiratory, thoracic and mediastinal disorders14/46254/46068/922
Cardiac failureCardiac disorders40/46251/46091/922
HypotensionVascular disorders44/46243/46087/922
Cardiac failure acuteCardiac disorders16/46231/46047/922

Baseline characteristics

Age, Continuous
Age, Continuous(years)Sacubitril/ValsartanEnalaprilTotal
Mean64.1 ± 10.664.2 ± 11.064.2 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)Sacubitril/ValsartanEnalaprilTotal
Female186201387
Male276259535
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Sacubitril/ValsartanEnalaprilTotal
Caucasian246256502
Black7070140
Indigenous241842
Mixed Ethnicity122116238
08

Study locations

79 sites
  • Novartis Investigative Site
    CABA, Buenos Aires C1221ADC, Argentina
  • Novartis Investigative Site
    CABA, Buenos Aires C1425BEI, Argentina
  • Novartis Investigative Site
    Ramos Mejía, Buenos Aires B1704ETD, Argentina
  • Novartis Investigative Site
    San Martín, Buenos Aires 1604, Argentina
  • Novartis Investigative Site
    Temperley, Buenos Aires 1834, Argentina
  • Novartis Investigative Site
    Villa María, Córdoba Province X5900JKA, Argentina
  • Novartis Investigative Site
    Salta, Salta Province A4406BPF, Argentina
  • Novartis Investigative Site
    San Miguel de Tucumán, San Miguel de Tucuman T4000ICL, Argentina
  • Novartis Investigative Site
    Rosario, Santa Fe Province 2000, Argentina
  • Novartis Investigative Site
    Rosario, Santa Fe Province S2000DIF, Argentina
  • Novartis Investigative Site
    San Miguel Tucuman, Tucumán Province T4000IFL, Argentina
  • Novartis Investigative Site
    San Miguel Tucuman, Tucumán Province T4000JCU, Argentina
  • Novartis Investigative Site
    Buenos Aires, C1155 AHD, Argentina
  • Novartis Investigative Site
    Corrientes, W3400CDS, Argentina
  • Novartis Investigative Site
    Córdoba, 5000, Argentina
  • Novartis Investigative Site
    Córdoba, X5003DCE, Argentina
  • Novartis Investigative Site
    Córdoba, X5004BAL, Argentina
  • Novartis Investigative Site
    Córdoba, X5006CBI, Argentina
  • Novartis Investigative Site
    Formosa, P3600, Argentina
  • Novartis Investigative Site
    Formosa, P3634XAR, Argentina
  • Novartis Investigative Site
    Mendoza, M5500CHC, Argentina
  • Novartis Investigative Site
    Santa Fe, S3000EOZ, Argentina
  • Novartis Investigative Site
    Santa Fe, S3000FWO, Argentina
  • Novartis Investigative Site
    Santiago del Estero, G4200AQK, Argentina
  • Novartis Investigative Site
    Fortaleza, Ceará 60125-025, Brazil
  • Novartis Investigative Site
    Fortaleza, Ceará 60430 370, Brazil
  • Novartis Investigative Site
    Salvador, Estado de Bahia 40050-410, Brazil
  • Novartis Investigative Site
    Salvador, Estado de Bahia 40110060, Brazil
  • Novartis Investigative Site
    Salvador, Estado de Bahia 40323-010, Brazil
  • Novartis Investigative Site
    Salvador, Estado de Bahia 41253-190, Brazil
  • Novartis Investigative Site
    Brasila, Federal District 70673623, Brazil
  • Novartis Investigative Site
    Brasília, Federal District 70390-700, Brazil
  • Novartis Investigative Site
    Brasília, Federal District 70673-416, Brazil
  • Novartis Investigative Site
    Goiânia, Goiás 74223-060, Brazil
  • Novartis Investigative Site
    Goiânia, Goiás 74223-130, Brazil
  • Novartis Investigative Site
    Goiânia, Goiás 74605-020, Brazil
  • Novartis Investigative Site
    São Luís, Maranhão 65020-070, Brazil
  • Novartis Investigative Site
    Belo Horizonte, Minas Gerais 30130-100, Brazil
  • Novartis Investigative Site
    Belo Horizonte, Minas Gerais 30140 062, Brazil
  • Novartis Investigative Site
    Belo Horizonte, Minas Gerais 30150-270, Brazil
  • Novartis Investigative Site
    Montes Claros, Minas Gerais 39401-001, Brazil
  • Novartis Investigative Site
    Passos, Minas Gerais 37904-020, Brazil
  • Novartis Investigative Site
    Uberaba, Minas Gerais 38025-440, Brazil
  • Novartis Investigative Site
    Uberlândia, Minas Gerais 38400 500, Brazil
  • Novartis Investigative Site
    Uberlândia, Minas Gerais 38400-328, Brazil
  • Novartis Investigative Site
    Londrina, Paraná 86038-440, Brazil
  • Novartis Investigative Site
    Belém, Pará 66087-660, Brazil
  • Novartis Investigative Site
    Recife, Pernambuco 50100-060, Brazil
  • Novartis Investigative Site
    Teresina, Piauí 64001-380, Brazil
  • Novartis Investigative Site
    Rio de Janeiro, Rio de Janeiro 20551-030, Brazil
  • Novartis Investigative Site
    Rio de Janeiro, Rio de Janeiro 22240-006, Brazil
  • Novartis Investigative Site
    Ijuí, Rio Grande do Sul 98700-000, Brazil
  • Novartis Investigative Site
    Botucatu, São Paulo 3880-1001, Brazil
  • Novartis Investigative Site
    Bragança Paulista, São Paulo 13183-091, Brazil
  • Novartis Investigative Site
    Campinas, São Paulo 13020-431, Brazil
  • Novartis Investigative Site
    Campinas, São Paulo 13060 080, Brazil
  • Novartis Investigative Site
    Campinas, São Paulo 13060-904, Brazil
  • Novartis Investigative Site
    Indaiatuba, São Paulo 13330-570, Brazil
  • Novartis Investigative Site
    Marília, São Paulo 17515-000, Brazil
  • Novartis Investigative Site
    Ribeirão Preto, São Paulo 14010-190, Brazil
  • Novartis Investigative Site
    Ribeirão Preto, São Paulo 14048-900, Brazil
  • Novartis Investigative Site
    Santo André, São Paulo 09080-001, Brazil
  • Novartis Investigative Site
    Sao Jose Rio Preto, São Paulo 15090-000, Brazil
  • Novartis Investigative Site
    São Paulo, São Paulo 04012 909, Brazil
  • Novartis Investigative Site
    São Paulo, São Paulo 05403-000, Brazil
  • Novartis Investigative Site
    Tatuí, São Paulo 18270-170, Brazil
  • Novartis Investigative Site
    Votuporanga, São Paulo 15500 003, Brazil
  • Novartis Investigative Site
    São Paulo, 05403-000, Brazil
  • Novartis Investigative Site
    São Paulo, 15015-210, Brazil
  • Novartis Investigative Site
    Bogota, Cundinamarca 110121, Colombia
  • Novartis Investigative Site
    Santa Marta, Magdalena Department 30360, Colombia
  • Novartis Investigative Site
    San Gil, Santander Department 684031, Colombia
  • Novartis Investigative Site
    Bogota DC, 110111, Colombia
  • Novartis Investigative Site
    Florida Blanca, 681001, Colombia
  • Novartis Investigative Site
    Floridablanca, 681004, Colombia
  • Novartis Investigative Site
    Mérida, Yucatán 97000, Mexico
  • Novartis Investigative Site
    Ciudad de, 14080, Mexico
  • Novartis Investigative Site
    Oaxaca City, 68000, Mexico
  • Novartis Investigative Site
    Xalapa, 91193, Mexico
09

References and documents

Publications

  • Lopes RD, Bocchi EA, Echeverria LE, Demacq C, de Barros E Silva PGM, Barbosa LM, Damiani L, Sayyed S, Yoshida LAF, Furtado RHM, Morillo CA, Kevorkian R, Ramires F, Bahit MC, Magana A, Chavez-Mendoza A, Miguel da Silva AH, Coelho da Silva A, Freitas AF Jr, Romano AA, Parneix A, Segura A, Franca CCB, Botta CE, de Barros E, Perna ER, Montenegro E, Quiroz Diaz FR, Feitosa-Filho GS, Severini GV, Molina I, Miranda JDSS, Sala J, Kerr Saraiva JF, Carbajales J, Maia LN, Santana Passos LC, Simoes MV, Moreira MDCV, Nunes MCP, Hernandes ME, Hominal M, Zarandon RS, Leon de la Fuente R, Aras R, Bazan SGZ, Luiz da Silva T Jr, Madrini V, de Oliveira WA Jr, Saporito WF, Gimpelewicz C, McMurray JJV; Prevention and Reduction of Adverse Outcomes in Chagasic Heart Failure Trial Evaluation (PARACHUTE-HF) Investigators. Sacubitril/Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: An Open-Label, Multicenter Randomized Clinical Trial. JAMA. 2026 Jan 6;335(1):49-59. doi: 10.1001/jama.2025.19808. PubMed 41335448 ↗
  • Bocchi EA, Echeverria LE, Demacq C, de Barros E Silva PGM, Mazza Barbosa L, Chiang LM, Damiani L, Morillo CA, Kevorkian R, Ramires F, Bahit MC, Ferrari A, Chavez-Mendoza A, Magana-Serrano JA, McMurray JJV, Gimpelewicz C, Lopes RD; PARACHUTE-HF Investigators. Sacubitril/Valsartan Versus Enalapril in Chronic Chagas Cardiomyopathy: Rationale and Design of the PARACHUTE-HF Trial. JACC Heart Fail. 2024 Aug;12(8):1473-1486. doi: 10.1016/j.jchf.2024.05.021. PubMed 39111953 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2019 to primary completion in Mar 2025, 63 months.

Results were first posted in May 2026, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2019
First posted
Jul 17, 2019
StartActual
Dec 10, 2019
Primary completionActual
Mar 16, 2025
CompletionActual
Mar 31, 2025
Results first posted
May 11, 2026
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04023227
Responsible party
Sponsor
First posted
Jul 17, 2019
Start date
Dec 10, 2019
Primary completion
Mar 16, 2025
Completion
Mar 31, 2025
Results posted
May 11, 2026
Last update
May 11, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sacubitril · Valsartan

Start the discussion